[CAS NO. 2376047-73-1]  SIAIS178

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2376047-73-1]

Catalog
AS979323
Brand
Arctom Scientific
CAS
2376047-73-1

DESCRIPTION [2376047-73-1]

Overview

MDL-
Molecular Weight1012.68
Molecular FormulaC50H62ClN11O6S2
SMILESO=C(N1CCN(C2=NC(C)=NC(NC3=NC=C(C(NC4=C(C=CC=C4Cl)C)=O)S3)=C2)CC1)CCCCCCC(N[C@@H](C(C)(C)C)C(N5[C@@H](C[C@@H](O)C5)C(NCC6=CC=C(C7=C(N=CS7)C)C=C6)=O)=O)=O

For research use only. We do not sell to patients.

Summary

SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC 50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity [1] .


IC50 & Target

VHL

Bcr-Abl

24 nM (IC 50 )


In Vitro

SIAIS178 (1-100 nM; for 16 hours) significantly reduces the BCR-ABL protein levels in a concentration dependent manner. SIAIS178 significantly inhibits the phosphorylation of BCR-ABL and the substrates STAT5 [1] .
SIAIS178 (1, 10, 100, 1000 nM) exerts significant antiproliferative activity in BCR-ABL driven CML cell lines. SIAIS178 retains potency and selectivity against the BCR-ABL driven cell lines [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis [1]

Cell Line: K562 cells
Concentration: 1, 3, 10, 30, 100 nM
Incubation Time: 16 hours
Result: Significantly reduced the BCR-ABL protein levels in a concentration dependent manner.

In Vivo

SIAIS178 (ip; 5, 15, and 45 mg/kg; 12 days) attenuates tumor progression in a dose-dependent manner, as determined by serial volumetric measurement [1] .
SIAIS178 (iv or ip; 2 mg/kg; 24 hours) has T 1/2 of 3.82 and 12.35 hours and C max of 1165.2 nM and 30 nM for iv and ip, respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID mice with termed K562-Luc [1]
Dosage: 5, 15, and 45 mg/kg
Administration: Ip; 12 days
Result: Attenuated tumor progression in a dose-dependent manner, as determined by serial volumetric measurement.
Animal Model: Female Wistar rats [1]
Dosage: 2 mg/kg (Pharmacokinetic Analysis)
Administration: Iv or ip; 24 hours
Result: Had T 1/2 of 3.82 and 12.35 hours and C max of 1165.2 nM and 30 nM for iv and ip, respectively.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 300 mg/mL ( 296.24 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.9875 mL 4.9374 mL 9.8748 mL
5 mM 0.1975 mL 0.9875 mL 1.9750 mL
10 mM 0.0987 mL 0.4937 mL 0.9875 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 7.5 mg/mL (7.41 mM); Clear solution

* All of the co-solvents are available by MCE.